Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galiximab Retreatment in Follicular NHL
NCT00384150Phase 3Terminated
- Sponsor
- Biogen
- Start
- Nov 2007
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of galiximab in follicular lymphoma (FL), sponsored by Biogen. Primary endpoints: Adverse Event Rates at 2 years, Clinical Laboratory Results at 2 years and 1 more. Started Nov 2007; status: terminated.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00384150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384150.